- CTI BioPharma (NASDAQ:CTIC) commences a public offering of its Series N-2 Preferred Stock at $1,000 per share. Net proceeds will fund the commercial launch of pacritinib in the U.S. for myelofibrosis, additional research into new indications for pacritinib, advancement of commercialization of PIXUVRI, support the clinical development of tosedostat and general corporate purposes.
- Volume and conversion terms are not disclosed yet, but the company's $50M Series N-1 Preferred Stock offering, executed in October, was convertible into 800 shares of common at a price of $1.25.
- Previously: CTI Bio prices $50M equity offering (Oct. 27)
- Previously: CTI Bio initiates rolling pacritinib NDA submission for rare bone marrow disorder (Nov. 23)